Article
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma.
Oncotarget - 20 May 2015
Bria Emilio, Pilotto Sara, Amato Eliana, Fassan Matteo, Novello Silvia, Peretti Umberto, Vavalà Tiziana, Kinspergher Stefania, Righi Luisella, Santo Antonio, Brunelli Matteo, Corbo Vincenzo, Giglioli Eliana, Sperduti Isabella, Milella Michele, Chilosi Marco, Scarpa Aldo, Tortora Giampaolo
Abstract excerpt
Cancer molecular heterogeneity might explain the variable response of EGFR mutant lung adenocarcinomas to tyrosine kinase inhibitors (TKIs). We assessed the mutational status of 22 cancer genes by next-generation sequencing (NGS) in poor, intermediate or good responders to first-line gefitinib. Clinical outcome was correlated with Additional Coexisting Mutations (ACMs) and the EGFR Proportion of Mutated Alleles...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.